ARTICLE | Finance
2023 catalysts: a buyside view
BioCentury’s 31st annual Buyside View finds that despite the extended downturn, investors see plenty of milestones to drive excitement this year
January 13, 2023 4:59 PM UTC
From critical commercial tests of newly approved gene therapies to the CV benefits of obesity drugs and further validation of amyloid as an Alzheimer’s target, buyside investors see a wide range of opportunities for substantial value creation in 2023 — and they’re not all about cancer.
Gone are the conditions of early last year when even strong data readouts failed to lift stocks, but positive catalysts will be essential for both market performance and fundraising again this year...
BCIQ Company Profiles